Skip to main content
SpringerLink
Log in

A Pharmacokinetic/Pharmacodynamic Approach to Predict Total Prednisolone Concentrations in Human Plasma

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Prednisolone and prednisone are two widely used corticosteroids for various inflammatory and immune diseases. Prednisolone is the active form of prednisone in vivo. Total prednisolone in plasma exhibits nonlinear pharmacokinetics mainly due to its nonlinear protein binding. Other factors such as reversible metabolism (or interconversion between prednisolone and prednisone), competitive protein binding from endogenous cortisol, cortisol circadian rhythm, and prednisolone mediated cortisol suppression complicate prednisolone pharmacokinetics. This study was aimed to develop a new approach to describe the nonlinear pharmacokinetics of total prednisolone and predict total prednisolone concentrations in plasma. Based on literature datasets, a linear two-compartment pharmacokinetic model was developed to adequately describe the reversible metabolism between free prednisone and prednisolone. Cortisol and prednisolone protein binding were described via the sum of a Langmuir and linear type binding. The endogenous cortisol circadian rhythm and cortisol suppression during prednisone or prednisolone exposure were described with a previously reported linear release rate pharmacokinetic/pharmacodynamic (PK/PD) model. By combining the pharmacokinetic models for free prednisone and prednisolone, the linear release rate model for cortisol suppression, and competitive protein binding between cortisol and prednisolone, we were able to predict total prednisolone concentrations in plasma. The predicted total prednisolone concentrations in plasma were in good agreement with the literature reported data. Thus, this PK/PD approach shows that the combination of nonlinear protein binding, cortisol circadian rhythm, and cortisol suppression could account for the nonlinearity of total prednisolone. In addition, it also allows a valid prediction of total prednisolone in plasma after either prednisone or prednisolone administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pickup M.E. (1979). Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet. 4:111–128

    PubMed  CAS  Google Scholar 

  2. Boudinot F.D., Jusko W.J. (1986). Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. J Pharmacokinet. Biopharm. 14:453–467

    Article  PubMed  CAS  Google Scholar 

  3. Frey F.J., Frey B.M., Greither A., Benet L.Z. (1980). Prednisolone clearance at steady state in dogs. J. Pharmacol. Exp. Ther. 215:287–291

    PubMed  CAS  Google Scholar 

  4. Huang M.L., Jusko W.J. (1990). Nonlinear pharmacokinetics and interconversion of prednisolone and prednisone in rats. J Pharmacokinet. Biopharm. 18:401–421

    Article  PubMed  CAS  Google Scholar 

  5. Pickup M.E., Lowe J.R., Leatham P.A., Rhind V.M., Wright V., Downie W.W. (1977). Dose dependent pharmacokinetics of prednisolone. Eur. J. Clin. Pharmacol. 12:213–219

    Article  PubMed  CAS  Google Scholar 

  6. Rose J.Q., Yurchak A.M., Jusko W.J. (1981). Dose dependent pharmacokinetics of prednisone and prednisolone in man. J. Pharmacokinet. Biopharm. 9:389–417

    Article  PubMed  CAS  Google Scholar 

  7. Wald J.A., Law R.M., Ludwig E.A., Sloan R.R., Middleton E. Jr., Jusko W.J. (1992). Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man. J. Pharmacokinet. Biopharm. 20:567–589

    Article  PubMed  CAS  Google Scholar 

  8. Ferry J.J., Wagner J.G. (1987). The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednisolone in rabbit and human plasma. Biopharm. Drug Dispos. 8:261–272

    Article  PubMed  CAS  Google Scholar 

  9. Jusko W.J., Rose J.Q. (1980). Monitoring prednisone and prednisolone. Ther. Drug Monit. 2:169–176

    Article  PubMed  CAS  Google Scholar 

  10. Rocci M.L. Jr., D’Ambrosio R., Johnson N.F., Jusko W.J. (1982). Prednisolone binding to albumin and transcortin in the presence of cortisol. Biochem. Pharmacol. 31:289–292

    Article  PubMed  CAS  Google Scholar 

  11. Legler U.F., Benet L.Z. (1986). The effect of prednisone and hydrocortisone on the plasma protein binding of prednisolone in man. Eur. J. Clin. Pharmacol. 30:51–55

    Article  PubMed  CAS  Google Scholar 

  12. Rohatagi S., Hochhaus G., Mollmann H., Barth J., Derendorf H. (1995). Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie 50:610–613

    PubMed  CAS  Google Scholar 

  13. Koopmans R.P., Braat M.C., Oosterhuis B., van Boxtel C.J. (1992). Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. J. Pharmacol. Exp. Ther. 262:503–508

    PubMed  CAS  Google Scholar 

  14. Rohatagi S., Bye A., Mackie A.E., Derendorf H. (1996). Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur. J. Pharmaceut. Sci. 4:341–350

    Article  CAS  Google Scholar 

  15. Chakraborty A., Krzyzanski W., Jusko W.J. (1999). Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J. Pharmacokinet. Biopharm. 27:23–43

    Article  PubMed  CAS  Google Scholar 

  16. Ferry J.J., Horvath A.M., Bekersky I., Heath E.C., Ryan C.F., Colburn W.A. (1988). Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J. Clin. Pharmacol. 28:81–87

    PubMed  CAS  Google Scholar 

  17. Chakraborty A., Blum R.A., Mis S.M., Cutler D.L., Jusko W.J. (1999). Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. J. Clin. Pharmacol. 39:624–635

    Article  PubMed  CAS  Google Scholar 

  18. Meno-Tetang G.M., Blum R.A., Schwartz K.E., Jusko W.J. (2001). Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J. Clin. Pharmacol. 41:1195–1205

    Article  PubMed  CAS  Google Scholar 

  19. D. Z. D’Argenio and A. Schumitzky. ADAPT II User’s Guide: Pharmacokinetic/pharmacodynamic Systems Analysis Software, 1997.

  20. Gustavson L.E., Benet L.Z. (1985). The macromolecular binding of prednisone in plasma of healthy volunteers including pregnant women and oral contraceptive users. J. Pharmacokinet. Biopharm. 13:561–569

    Article  PubMed  CAS  Google Scholar 

  21. Derendorf H., Mollmann H., Barth J., Mollmann C., Tunn S., Krieg M. (1991). Pharmacokinetics and oral bioavailability of hydrocortisone. J. Clin. Pharmacol. 31:473–476

    PubMed  CAS  Google Scholar 

  22. Boudinot F.D., Jusko W.J. (1984). Plasma protein binding interaction of prednisone and prednisolone. J. Steroid Biochem. 21:337–339

    Article  PubMed  CAS  Google Scholar 

  23. W. E. Evans, J. J. Schentag, and W. J. Jusko. Applied Pharmacokinetics : Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins, Vancouver, 1992, p. Ch27.

  24. Baxter J.D., Rousseau G.G. (1979), Glucocorticoid Hormone Action. Monographs on Endocrinology, Vol. 12. Springer-Verlag, Berlin, New York, pp. 26–27

    Google Scholar 

  25. Garg V., Jusko W.J. (1994). Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos. 15:163–172

    Article  PubMed  CAS  Google Scholar 

  26. Schwartz J.I., Mukhopadhyay S., Porras A.G., Viswanathan-Aiyer K.J., Adcock S., Ebel D.L., Gertz B.J. (2003). Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 43:187–192

    Article  PubMed  CAS  Google Scholar 

  27. Frey B.M., Frey F.J. (1990). Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet. 19:126–146

    Article  PubMed  CAS  Google Scholar 

  28. Gambertoglio J.G., Amend W.J. Jr., Benet L.Z. (1980). Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J. Pharmacokinet. Biopharm. 8:1–52

    Article  PubMed  CAS  Google Scholar 

  29. Frey F.J., Ruegsegger M.K., Frey B.M. (1986). The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone. Br. J. Clin. Pharmacol. 21:183–189

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, College of Pharmacy, University of Florida, 1600 SW Archer Rd., P.O. Box 100494, Gainesville, FL, 32610-0434, USA

    J. Xu, J. Winkler & H. Derendorf

Authors
  1. J. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Derendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Derendorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, J., Winkler, J. & Derendorf, H. A Pharmacokinetic/Pharmacodynamic Approach to Predict Total Prednisolone Concentrations in Human Plasma. J Pharmacokinet Pharmacodyn 34, 355–372 (2007). https://doi.org/10.1007/s10928-007-9050-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-007-9050-8

Keywords

Search

Navigation